{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:35:22Z","timestamp":1791502522000,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHLT Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jhlto.2026.100494","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:51:01Z","timestamp":1768895461000},"page":"100494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Invasive aspergillosis in lung and heart transplant recipients"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9575","authenticated-orcid":false,"given":"C. Orla","family":"Morrissey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhlto.2026.100494_bib1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.healun.2018.06.008","article-title":"Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study","volume":"37","author":"Aguilar","year":"2018","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib2","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1086\/376527","article-title":"Invasive aspergillosis in the setting of cardiac transplantation","volume":"37","author":"Montoya","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1053-2498(02)00477-1","article-title":"Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management","volume":"22","author":"Singh","year":"2003","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1469-0691.2005.01128.x","article-title":"Aspergillus infections in lung transplant recipients: risk factors and outcome","volume":"11","author":"Sol\u00e9","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhlto.2026.100494_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: incidence and prognosis","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/00365548.2012.691207","article-title":"Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients","volume":"44","author":"Tofte","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12898","article-title":"Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study","volume":"20","author":"Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib9","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1097\/TP.0000000000003187","article-title":"Late onset invasive pulmonary aspergillosis in lung transplant recipients in the setting of a targeted prophylaxis\/preemptive antifungal therapy strategy","volume":"104","author":"Herrera","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100494_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.healun.2021.09.014","article-title":"Risk factors of invasive fungal infections in lung transplant recipients: a systematic review and meta-analysis","volume":"41","author":"Phoompoung","year":"2022","journal-title":"J\u00a0Heart\u00a0Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70020","article-title":"Aspergillus after lung transplantation: prophylaxis, risk factors, and the impact on chronic lung allograft dysfunction","volume":"27","author":"Gemert","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib12","first-page":"774","article-title":"Airway stenoses after lung transplantation: management with expanding metal stents","volume":"13","author":"Higgins","year":"1994","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00007890-200101270-00013","article-title":"Hypogammaglobulinemia in lung transplant recipients","volume":"71","author":"Goldfarb","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100494_bib14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.healun.2023.02.005","article-title":"Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year","volume":"42","author":"Permpalung","year":"2023","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib15","doi-asserted-by":"crossref","first-page":"e1379","DOI":"10.1093\/cid\/ciac551","article-title":"Statin use may be associated with a lower risk of invasive aspergillosis in lung transplant recipients","volume":"76","author":"Villalobos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib16","first-page":"589","article-title":"Antifungal activity of statins against Aspergillus species","volume":"45","author":"Qiao","year":"2007","journal-title":"Med\u00a0Mycol"},{"key":"10.1016\/j.jhlto.2026.100494_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jhlto.2026.100494_bib18","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhlto.2026.100494_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1432-2277.2012.01499.x","article-title":"Fungal infection in cardiothoracic transplant recipients: outcome without systemic amphotericin therapy","volume":"25","author":"Dhar","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhlto.2026.100494_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2004.00390.x","article-title":"Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis","volume":"4","author":"Mu\u00f1oz","year":"2004","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.TP.0000044358.99414.B8","article-title":"The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis","volume":"75","author":"Mu\u00f1oz","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100494_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13367","article-title":"A case-control study of the risk factors for developing aspergillosis following cardiac transplant","volume":"32","author":"Cook","year":"2018","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.healun.2014.05.003","article-title":"Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis","volume":"33","author":"Mu\u00f1oz","year":"2014","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.healun.2011.01.701","article-title":"A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients","volume":"30","author":"Husain","year":"2011","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-3062.2010.00499.x","article-title":"Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients","volume":"12","author":"Park","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jinf.2013.03.013","article-title":"Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis","volume":"67","author":"Singh","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.jhlto.2026.100494_bib27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crad.2012.02.018","article-title":"Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation","volume":"67","author":"Lim","year":"2012","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jhlto.2026.100494_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14404","article-title":"A 2-year review of the diagnostic performance of serum and Bronchoalveolar Lavage Galactomannan testing in lung transplant recipients in a National Heart and Lung Transplant Centre","volume":"27","author":"O'Donnell","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib30","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/01.tp.0000263992.41003.33","article-title":"Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients","volume":"83","author":"Husain","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100494_bib31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JCM.00077-07","article-title":"Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients","volume":"45","author":"Clancy","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhlto.2026.100494_bib32","first-page":"173","article-title":"1,3) \u03b2-D-Glucan in bronchoalveolar lavage of lung transplant recipients for the diagnosis of invasive pulmonary aspergillosis","volume":"55","author":"Bhaskaran","year":"2016","journal-title":"Med\u00a0Mycol"},{"key":"10.1016\/j.jhlto.2026.100494_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s10096-011-1244-8","article-title":"Reactivity of (1\u21923)-\u03b2-d-glucan assay in bacterial bloodstream infections","volume":"30","author":"Albert","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14136","article-title":"Systematic fungal biomarker or polymerase chain reaction testing in lung transplant recipients: Retrospective analysis to optimize their use","volume":"25","author":"Boutin","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib35","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/cid\/cir185","article-title":"Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients","volume":"52","author":"Luong","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13811","article-title":"Routine comprehensive Aspergillus screening of bronchoalveolar lavage samples in lung transplant recipients","volume":"34","author":"Unterman","year":"2020","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061545","article-title":"Evaluation of MycAssay\u2122 aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer","volume":"8","author":"Guinea","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.jhlto.2026.100494_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/jof4030103","article-title":"Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant aspergillus fumigatus isolates","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi"},{"key":"10.1016\/j.jhlto.2026.100494_bib39","doi-asserted-by":"crossref","unstructured":"Guinea J. Updated EUCAST Clinical breakpoints against aspergillus, implications for the clinical microbiology laboratory. J Fungi 2020;6(4):343. Available at: https:\/\/www.mdpi.com\/2309\u2013608X\/6\/4\/343.","DOI":"10.3390\/jof6040343"},{"key":"10.1016\/j.jhlto.2026.100494_bib40","first-page":"211","article-title":"Comparison between cytologic examination of fungi in bronchial washings and bronchoalveolar lavage specimens and culture: a review of 100 cases with emphasis on diagnostic pitfalls","volume":"3","author":"Crumley","year":"2014","journal-title":"J\u00a0Am\u00a0Soc\u00a0Cytopathol"},{"key":"10.1016\/j.jhlto.2026.100494_bib41","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s15010-017-1072-6","article-title":"Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience","volume":"45","author":"Lass-Fl\u00f6rl","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jhlto.2026.100494_bib43","first-page":"796","article-title":"Prospective assessment of Platelia\u2122\u00a0aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients","volume":"4","author":"Husain","year":"2004","journal-title":"Am\u00a0J\u00a0Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib44","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00598-21","article-title":"Performance of the s\u014dna Aspergillus Galactomannan lateral flow assay in a cancer patient population","volume":"59","author":"Jani","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhlto.2026.100494_bib46","first-page":"3478","article-title":"Point-counterpoint: \u03b2-d-glucan testing is important for diagnosis of invasive fungal infections","volume":"51","author":"Theel","year":"2013","journal-title":"J\u00a0Clin\u00a0Microbiol"},{"key":"10.1016\/j.jhlto.2026.100494_bib47","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JCM.00467-14","article-title":"Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"52","author":"Hoenigl","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhlto.2026.100494_bib48","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.healun.2023.02.213","article-title":"(197) Aspergillus droplet digital PCR (ddPCR)in exhaled breath condensate for the diagnosis of invasive aspergillosis (IA) in lung transplant recipients (LTRs)","volume":"42","author":"Runyo","year":"2023","journal-title":"J\u00a0Heart\u00a0Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib49","article-title":"Diagnosis of invasive pulmonary aspergillosis using metagenomic next-generation sequencing and conventional microbial tests post-COVID-19 pandemic","volume":"13","author":"Li","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jhlto.2026.100494_bib50","article-title":"The clinical utility of bronchoalveolar lavage fluid metagenomic next-generation sequencing in immunocompromised critically ill patients with invasive pulmonary aspergillosis: a multicenter retrospective study","volume":"13","author":"Zhao","year":"2025","journal-title":"Microbiol\u00a0Spect"},{"key":"10.1016\/j.jhlto.2026.100494_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhlto.2026.100494_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib53","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib54","first-page":"1619","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin\u00a0Infect\u00a0Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation--a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11908-013-0380-y","article-title":"Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis","volume":"15","author":"Bhaskaran","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jhlto.2026.100494_bib57","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/jof9111079","article-title":"Invasive aspergillosis among lung transplant recipients during time periods with universal and targeted antifungal prophylaxis-a nationwide cohort study","volume":"9","author":"Crone","year":"2023","journal-title":"J Fungi"},{"key":"10.1016\/j.jhlto.2026.100494_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13448","article-title":"Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib60","doi-asserted-by":"crossref","unstructured":"Hosseini-Moghaddam SM, Chaparro C, Luong M-L, et al. The effectiveness of culture-directed preemptive anti-aspergillus treatment in lung transplant recipients at one year after transplant. Transplantation 2015;99(11). Available at: https:\/\/journals.lww.com\/transplantjournal\/fulltext\/2015\/11000\/the_effectiveness_of_culture_directed_preemptive.27.aspx.","DOI":"10.1097\/TP.0000000000000743"},{"key":"10.1016\/j.jhlto.2026.100494_bib61","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/cid\/cir771","article-title":"Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit","volume":"54","author":"Pel\u00e1ez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib62","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/TP.0b013e31829e6d7b","article-title":"Targeted antifungal prophylaxis in heart transplant recipients","volume":"96","author":"Mu\u00f1oz","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jhlto.2026.100494_bib63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhlto.2026.100494_bib64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhlto.2026.100494_bib65","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhlto.2026.100494_bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib67","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhlto.2026.100494_bib69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/myc.12911","article-title":"Posaconazole salvage therapy: the Posifi study","volume":"62","author":"Fortun","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.jhlto.2026.100494_bib70","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s40121-024-01064-4","article-title":"Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019)","volume":"13","author":"Neofytos","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jhlto.2026.100494_bib71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib72","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1080\/13693780802537953","article-title":"Cerebral aspergillosis: tissue penetration is the key","volume":"47","author":"Schwartz","year":"2009","journal-title":"Med Mycol"},{"key":"10.1016\/j.jhlto.2026.100494_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3341\/kjo.2009.23.1.46","article-title":"Topical and oral voriconazole in the treatment of fungal keratitis","volume":"23","author":"Lee","year":"2009","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jhlto.2026.100494_bib74","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jac\/dkm023","article-title":"Voriconazole concentrations in synovial fluid and bone tissues","volume":"59","author":"Denes","year":"2007","journal-title":"J\u00a0Antimicrobial Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5694\/mja13.00214","article-title":"Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia","volume":"201","author":"Neoh","year":"2014","journal-title":"Med J Aust"},{"key":"10.1016\/j.jhlto.2026.100494_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib77","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia","volume":"40","author":"Fleming","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jhlto.2026.100494_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035478","article-title":"Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities","volume":"7","author":"Ingham","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhlto.2026.100494_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.farma.2023.07.010","article-title":"Characterization and real-live results of nebulized voriconazole: a single-center observational study","volume":"48","author":"Larrosa-Garcia","year":"2024","journal-title":"Farmacia Hospitalaria"},{"key":"10.1016\/j.jhlto.2026.100494_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14264","article-title":"Voriconazole inhalation powder: a novel therapeutic alternative for invasive pulmonary fungal infections","volume":"26","author":"Gardiner","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coph.2015.07.002","article-title":"Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice","volume":"24","author":"Lempers","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jhlto.2026.100494_bib83","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jhlto.2026.100494_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00970-17","article-title":"Effects of isavuconazole on the plasma concentrations of tacrolimus among solid-organ transplant patients","volume":"61","author":"Rivosecchi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib85","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.healun.2017.01.634","article-title":"Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis","volume":"36","author":"Butler-Laporte","year":"2017","journal-title":"J\u00a0Heart\u00a0Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib86","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jac\/dkx440","article-title":"Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations","volume":"73","author":"Jeong","year":"2017","journal-title":"J\u00a0Antimicrobial Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib87","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/antibiotics12091399","article-title":"Dosing optimization of posaconazole in lung-transplant recipients based on population pharmacokinetic model","volume":"12","author":"Dvo\u0159\u00e1\u010dkov\u00e1","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jhlto.2026.100494_bib88","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","article-title":"Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity","volume":"56","author":"Mitsani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib89","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/j.healun.2024.02.1022","article-title":"The rationale for therapeutic drug monitoring of isavuconazole in a lung transplant recipient","volume":"43","author":"Zajacova","year":"2024","journal-title":"J\u00a0Heart\u00a0Lung Transpl"},{"key":"10.1016\/j.jhlto.2026.100494_bib90","first-page":"117","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)","volume":"26","author":"Pfaller","year":"2021","journal-title":"J\u00a0Glob\u00a0Antimicrob\u00a0Resist"},{"key":"10.1016\/j.jhlto.2026.100494_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01132-23","article-title":"In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)","volume":"68","author":"Pfaller","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00682-21","article-title":"In vitro activity of APX2041, a New Gwt1 inhibitor, and in vivo efficacy of the prodrug APX2104 against aspergillus fumigatus","volume":"65","author":"Shaheen","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib93","first-page":"e302","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by aspergillus species and rare molds: a phase 2, open-label study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin\u00a0Infect\u00a0Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib94","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/jof7030232","article-title":"In vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies","volume":"7","author":"Rivero-Menendez","year":"2021","journal-title":"J Fungi"},{"key":"10.1016\/j.jhlto.2026.100494_bib95","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1207","article-title":"SCY-078 demonstrates significant antifungal activity in a murine model of invasive aspergillosis","volume":"4","author":"Borroto-Esoda","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/jof7050378","article-title":"In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents","volume":"7","author":"Georgacopoulos","year":"2021","journal-title":"J Fungi"},{"key":"10.1016\/j.jhlto.2026.100494_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib98","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhlto.2026.100494_bib99","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrobial Agents\u00a0Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib100","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib101","article-title":"Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and pneumocystis pneumonia","volume":"65","author":"Miesel","year":"2021","journal-title":"Antimicrobial Agents\u00a0Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib102","first-page":"505","article-title":"The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis","volume":"58","author":"Garvey","year":"2019","journal-title":"Med\u00a0Mycol"},{"key":"10.1016\/j.jhlto.2026.100494_bib103","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myae032","article-title":"Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598","volume":"62","author":"Gu","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.jhlto.2026.100494_bib104","first-page":"404","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2017","journal-title":"J\u00a0Antimicrob\u00a0Chemother"},{"key":"10.1016\/j.jhlto.2026.100494_bib105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2023.2203383","article-title":"The antifungal pipeline for invasive fungal diseases: What does the future hold?","volume":"21","author":"Neoh","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jhlto.2026.100494_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"}],"container-title":["JHLT Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133426000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133426000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:40:40Z","timestamp":1779284440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950133426000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":106,"alternative-id":["S2950133426000157"],"URL":"https:\/\/doi.org\/10.1016\/j.jhlto.2026.100494","relation":{},"ISSN":["2950-1334"],"issn-type":[{"value":"2950-1334","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive aspergillosis in lung and heart transplant recipients","name":"articletitle","label":"Article Title"},{"value":"JHLT Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhlto.2026.100494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}],"article-number":"100494"}}